Business Description
Hepion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Share Class Description:
CTRVW: Warrants (03/07/2023)Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.73 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.04 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 33.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.3 | |||||
| 3-Year FCF Growth Rate | 32.6 | |||||
| 3-Year Book Growth Rate | -63.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.62 | |||||
| Quick Ratio | 5.62 | |||||
| Cash Ratio | 2.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.4 | |||||
| Shareholder Yield % | -3.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -232.91 | |||||
| ROA % | -139.6 | |||||
| ROIC % | -1055.87 | |||||
| 3-Year ROIIC % | 476.68 | |||||
| ROC (Joel Greenblatt) % | -5234.34 | |||||
| ROCE % | -230.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.99 | |||||
| EV-to-EBIT | -0.09 | |||||
| EV-to-EBITDA | -0.1 | |||||
| EV-to-FCF | -0.1 | |||||
| Earnings Yield (Greenblatt) % | -1111.11 | |||||
| FCF Yield % | -937.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CTRVW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hepion Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0 - 0.25 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hepion Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hepion Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hepion Pharmaceuticals Inc Frequently Asked Questions
What is Hepion Pharmaceuticals Inc(CTRVW)'s stock price today?
The current price of CTRVW is $0.00. The 52 week high of CTRVW is $0.25 and 52 week low is $0.00.
When is next earnings date of Hepion Pharmaceuticals Inc(CTRVW)?
The next earnings date of Hepion Pharmaceuticals Inc(CTRVW) is 2024-11-20 Est..
Does Hepion Pharmaceuticals Inc(CTRVW) pay dividends? If so, how much?
Hepion Pharmaceuticals Inc(CTRVW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers